SRPT
NASDAQ
US
Sarepta Therapeutics, Inc. - Common Stock
$23.23
▲ +$1.10
(+4.97%)
Vol 3.1M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.3B
ROE
-20.3%
Margin
-11.3%
D/E
78.41
Beta
0.39
52W
$10–$130
Wall Street Consensus
33 analysts · Apr 20267
Strong Buy
6
Buy
15
Hold
4
Sell
1
Strong Sell
39.4%
Buy Rating
Price Chart
Similar Stocks
VCYT
Veracyte Inc
P/E 110.3
$3.3B
BEAM
Beam Therapeutics Inc
$2.8B
IRON
Disc Medicine Inc
$3.0B
KOD
Kodiak Sciences Inc
$1.7B
IMNM
Immunome Inc
$2.4B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.26 | $-3.93 | $-2.67 |
| Sep 2025 | $-0.83 | $-0.01 | +$0.82 |
| Jun 2025 | $0.77 | $1.89 | +$1.12 |
| Mar 2025 | $-0.97 | $-4.60 | $-3.63 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -4.4% | -4.4% | -4.4% | -4.4% | -20.3% | -20.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 32.2% | -2.3% | -2.3% | -2.3% | -11.2% | -11.2% |
| Gross Margin | 75.0% | 79.3% | 79.3% | 79.3% | 76.2% | 76.2% |
| D/E Ratio | 83.95 | 83.95 | 83.95 | 83.95 | 78.41 | 78.41 |
| Current Ratio | 2.89 | 2.89 | 2.89 | 2.89 | 2.95 | 2.95 |
Key Ratios
ROA (TTM)
-7.4%
P/S (TTM)
0.93
P/B
7.6
EPS (TTM)
$-3.35
CF/Share
$-7.32
Rev Growth 3Y
+39.4%
52W High
$129.84
52W Low
$10.42
$10.42
52-Week Range
$129.84
How does SRPT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SRPT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0.9
▼
93%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
7.6
▲
209%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SRPT profitability vs Biotechnology peers
ROE
-20.3%
▲
70%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-11.3%
▲
96%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
76.3%
▼
3%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-7.4%
▲
84%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
SRPT financial health vs Biotechnology peers
D/E ratio
78.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.0
▼
33%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
60%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SRPT fundamentals radar
SRPT
Peer median
Industry
SRPT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio